Enanta Pharmaceuticals, Inc. Stock price
Equities
ENTA
US29251M1062
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.53 USD | +3.64% | +14.00% | +75.66% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
Financials (USD)
Sales 2024 * | 68.81M | Sales 2025 * | 73.31M | Capitalization | 350M |
---|---|---|---|---|---|
Net income 2024 * | -110M | Net income 2025 * | -116M | EV / Sales 2024 * | 5.08 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.77 x |
P/E ratio 2024 * |
-3.17
x | P/E ratio 2025 * |
-3.35
x | Employees | 145 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.9% |
Latest transcript on Enanta Pharmaceuticals, Inc.
1 day | +3.64% | ||
1 week | +14.00% | ||
Current month | +15.03% | ||
1 month | +17.65% | ||
3 months | +71.30% | ||
6 months | +43.74% | ||
Current year | +75.66% |
Managers | Title | Age | Since |
---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 03-06-30 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 03-08-31 |
Chief Tech/Sci/R&D Officer | 50 | 22-08-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 20-06-28 |
Lesley Russell
BRD | Director/Board Member | 63 | 16-11-17 |
Bruce Carter
CHM | Chairman | 80 | 13-11-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 16.53 | +3.64% | 476,790 |
24-03-26 | 15.95 | +14.42% | 477,223 |
24-03-25 | 13.94 | -4.46% | 132,434 |
24-03-22 | 14.59 | -0.27% | 392,276 |
24-03-21 | 14.63 | +0.90% | 396,626 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.66% | 350M | |
+9.16% | 45.97B | |
+53.41% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |